Clinical trial details

A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC P115 C as a Single Agent and in Combination with Standard of Care Agents in HLA A*02:01 Positive Participants with Advanced PRAME Positive Cancers

Identifier

IMC-P115C-1005

Sponsor

IMMUNOCORE, LTD.

Principal Investigator

ANA OAKNIN BENZAQUEN

Service

Oncology

Study details

Tumor type: ALL SOLID TUMORS
Stage: Advanced
Main Investigational Agent : Biespecific antibodies
Phase: I
Randomization: Non-randomized

Molecular details

Biomarker: HLA-A2 pos
Biomarker criteria: Mandatory
Prescreening: Local
Additional study population requirements: IMC-P115C is a novel bispecific protein therapy developed by Immunocore, a biotechnology company specializing in T cell receptor (TCR) technology. This drug candidate is designed to target PRAME (PReferentially expressed Antigen in MElanoma) in cancer cells Population criteria: Patient Population: HLA-A*02:01-positive patients with advanced solid tumors expressing PRAME

Drug details

Arm A: IMC-P115C
Arm B: IMC-P115C AND standard of care agents (to be determined based on initial results)

Links

Clinical Trials GOV (NCT identifier): NL
EU Clinical Trials Register (eudraCT Identifier): 2023-509767-25